Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 390

1.

Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma.

Kotani K, Enomoto M, Okada M, Yoshida K, Motoyama H, Fujii H, Hagihara A, Uchida-Kobayashi S, Morikawa H, Murakami Y, Tamori A, Kawada N.

Clin J Gastroenterol. 2019 Apr 24. doi: 10.1007/s12328-019-00983-x. [Epub ahead of print]

PMID:
31020569
2.

Obesity worsens the outcome of influenza virus infection associated with impaired type I interferon induction in mice.

Namkoong H, Ishii M, Fujii H, Asami T, Yagi K, Suzuki S, Azekawa S, Tasaka S, Hasegawa N, Betsuyaku T.

Biochem Biophys Res Commun. 2019 May 28;513(2):405-411. doi: 10.1016/j.bbrc.2019.03.211. Epub 2019 Apr 6.

PMID:
30967261
3.

One-Year Impact of Kidney Transplantation on Cardiac Abnormalities and Blood Pressure in Hemodialysis Patients.

Fujii H, Watanabe S, Kono K, Watanabe K, Goto S, Ishimura T, Fujisawa M, Nishi S.

Ther Apher Dial. 2019 Apr 2. doi: 10.1111/1744-9987.12808. [Epub ahead of print]

PMID:
30941871
4.

Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis.

Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, Fujii H, Wu Y, Kam LY, Ji F, Li X, Chien N, Wei M, Ogawa E, Zhao C, Wu X, Stave CD, Henry L, Barnett S, Takahashi H, Furusyo N, Eguchi Y, Hsu YC, Lee TY, Ren W, Qin C, Jun DW, Toyoda H, Wong VW, Cheung R, Zhu Q, Nguyen MH.

Lancet Gastroenterol Hepatol. 2019 May;4(5):389-398. doi: 10.1016/S2468-1253(19)30039-1. Epub 2019 Mar 20.

PMID:
30902670
5.

Characteristics of coronary artery disease in chronic kidney disease.

Fujii H, Kono K, Nishi S.

Clin Exp Nephrol. 2019 Jun;23(6):725-732. doi: 10.1007/s10157-019-01718-5. Epub 2019 Mar 4. Review.

6.

Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis.

Honda A, Tanaka A, Kaneko T, Komori A, Abe M, Inao M, Namisaki T, Hashimoto N, Kawata K, Takahashi A, Ninomiya M, Kang JH, Arakawa M, Yamagiwa S, Joshita S, Umemura T, Sato K, Kaneko A, Kikuchi K, Itakura J, Nomura T, Kakisaka K, Fujii H, Kawada N, Takikawa Y, Masaki T, Ohira H, Mochida S, Yoshiji H, Iimuro S, Matsuzaki Y, Takikawa H; Japan PBC Study Group.

Hepatology. 2019 Feb 8. doi: 10.1002/hep.30552. [Epub ahead of print]

PMID:
30737815
7.

Use of a Reinforced Triple-row Stapler Following Distal Pancreatectomy Reduces the Incidence of Postoperative Pancreatic Fistula in Patients With a High BMI.

Kawaida H, Kono H, Amemiya H, Hosomura N, Saito R, Takahashi K, Yamamoto A, Watanabe M, Furuya S, Shimizu H, Akaike H, Kawaguchi Y, Sudo M, Matusda M, Itakura J, Fujii H, Ichikawa D.

Anticancer Res. 2019 Feb;39(2):1013-1018. doi: 10.21873/anticanres.13207.

PMID:
30711989
8.

[CKD-MBD and cardiovascular disease.]

Fujii H.

Clin Calcium. 2019;29(2):179-184. doi: 10.20837/4201902179. Japanese.

PMID:
30679398
9.

Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis.

Kodama K, Kawaguchi T, Hyogo H, Nakajima T, Ono M, Seike M, Takahashi H, Nozaki Y, Kawanaka M, Tanaka S, Imajo K, Sumida Y, Kamada Y, Fujii H, Seko Y, Takehara T, Itoh Y, Nakajima A, Masaki N, Torimura T, Saibara T, Karino Y, Chayama K, Tokushige K.

J Gastroenterol Hepatol. 2019 Jan 22. doi: 10.1111/jgh.14608. [Epub ahead of print]

PMID:
30668889
10.

HOMA-IR: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease.

Fujii H, Imajo K, Yoneda M, Nakahara T, Hyogo H, Takahashi H, Hara T, Tanaka S, Sumida Y, Eguchi Y, Chayama K, Nakajima A, Nishimoto N, Kawada N; Japan Study Group of Nonalcoholic Fatty Liver Disease.

J Gastroenterol Hepatol. 2019 Jan 1. doi: 10.1111/jgh.14595. [Epub ahead of print]

PMID:
30600551
11.

Changes in serum and intracardiac fibroblast growth factor 23 during the progression of left ventricular hypertrophy in hypertensive model rats.

Fujii H, Watanabe K, Kono K, Goto S, Watanabe S, Nishi S.

Clin Exp Nephrol. 2019 May;23(5):589-596. doi: 10.1007/s10157-018-1680-1. Epub 2018 Dec 11.

PMID:
30539338
12.

Essential points from Evidence-based Clinical Practice Guidelines for Chronic Kidney Disease 2018.

Japanese Society of Nephrology.

Clin Exp Nephrol. 2019 Jan;23(1):1-15. doi: 10.1007/s10157-018-1648-1. No abstract available.

13.

Feasibility of Combination Therapy with Nab-paclitaxel Plus Gemcitabine in Patients with Recurrent Pancreatic Cancer.

Kawaida H, Kono H, Amemiya H, Saitou R, Yamamoto A, Hosomura N, Watanabe M, Kimura A, Furuya S, Shimizu H, Akaike H, Kawaguchi Y, Sudo M, Itakura J, Hayakawa H, Shindo H, Takahashi EI, Takano S, Fukasawa M, Ichikawa S, Fujii H, Ichikawa D.

Anticancer Res. 2018 Nov;38(11):6537-6542. doi: 10.21873/anticanres.13019.

PMID:
30396983
14.

Short-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C.

Enomoto M, Ikura Y, Tamori A, Kozuka R, Motoyama H, Kawamura E, Hagihara A, Fujii H, Uchida-Kobayashi S, Morikawa H, Murakami Y, Kawada N.

United European Gastroenterol J. 2018 Nov;6(9):1391-1400. doi: 10.1177/2050640618791053. Epub 2018 Jul 19.

15.

Changes in plasma interleukin-8 and tumor necrosis factor-α levels during the early treatment period as a predictor of the response to sorafenib in patients with unresectable hepatocellular carcinoma.

Iida-Ueno A, Enomoto M, Uchida-Kobayashi S, Hagihara A, Teranishi Y, Fujii H, Morikawa H, Murakami Y, Tamori A, Thuy LTT, Kawada N.

Cancer Chemother Pharmacol. 2018 Nov;82(5):857-864. doi: 10.1007/s00280-018-3681-x. Epub 2018 Sep 3.

PMID:
30178114
16.

Hepatic ductoplasty for iatrogenic Bismuth type 2 bile duct stricture: A case report.

Hirotaka O, Takahashi K, Hiroyuki W, Kawashima K, Ichikawa D, Hideki F.

Int J Surg Case Rep. 2018;51:161-164. doi: 10.1016/j.ijscr.2018.08.025. Epub 2018 Aug 19.

17.

Association between HLA-DQA1/DRB1 polymorphism and development of hepatocellular carcinoma during entecavir treatment.

Kozuka R, Enomoto M, Sato-Matsubara M, Yoshida K, Motoyama H, Hagihara A, Fujii H, Uchida-Kobayashi S, Morikawa H, Tamori A, Kawada N, Murakami Y.

J Gastroenterol Hepatol. 2019 May;34(5):937-946. doi: 10.1111/jgh.14454. Epub 2018 Sep 26.

PMID:
30160782
18.

Clinical Impact of Histological Heterogeneity in the Metastatic Lymph Nodes of Patients with Colorectal Cancer.

Hirayama K, Sudoh M, Shimizu H, Furuya S, Akazawa Y, Iino H, Shiraishi K, Akaike H, Hosomura N, Kawaguchi Y, Amemiya H, Kawaida H, Inoue S, Kono H, Fujii H, Ichikawa D.

Anticancer Res. 2018 Aug;38(8):4797-4803. doi: 10.21873/anticanres.12789.

PMID:
30061251
19.

A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD.

Kawaguchi T, Tokushige K, Hyogo H, Aikata H, Nakajima T, Ono M, Kawanaka M, Sawada K, Imajo K, Honda K, Takahashi H, Mori K, Tanaka S, Seko Y, Nozaki Y, Kamada Y, Fujii H, Kawaguchi A, Takehara T, Yanase M, Sumida Y, Eguchi Y, Seike M, Yoneda M, Suzuki Y, Saibara T, Karino Y, Chayama K, Hashimoto E, George J, Torimura T.

Sci Rep. 2018 Jul 11;8(1):10434. doi: 10.1038/s41598-018-28650-0.

20.

Correction to: The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study.

Ishiba H, Sumida Y, Tanaka S, Yoneda M, Hyogo H, Ono M, Fujii H, Eguchi Y, Suzuki Y, Yoneda M, Takahashi H, Nakahara T, Seko Y, Mori K, Kanemasa K, Shimada K, Imai S, Imajo K, Kawaguchi T, Nakajima A, Chayama K, Saibara T, Shima T, Fujimoto K, Okanoue T, Itoh Y; Japan Study Group of Non-Alcoholic Fatty Liver Disease (JSG-NAFLD).

J Gastroenterol. 2018 Nov;53(11):1225. doi: 10.1007/s00535-018-1478-7.

PMID:
29802457

Supplemental Content

Loading ...
Support Center